Dominari Holdings's book value per share for the quarter that ended in Dec. 2023 was $8.92.
During the past 12 months, Dominari Holdings's average Book Value Per Share Growth Rate was -39.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -14.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -34.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -47.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Dominari Holdings was -14.80% per year. The lowest was -83.60% per year. And the median was -37.75% per year.
Dominari Holdings's current price is $2.70. Its book value per share for the quarter that ended in Dec. 2023 was $8.92. Hence, today's PB Ratio of Dominari Holdings is 0.30.
During the past 13 years, the highest P/B Ratio of Dominari Holdings was 5.65. The lowest was 0.17. And the median was 0.65.
Dominari Holdings Book Value per Share Historical Data
The historical data trend for Dominari Holdings's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dominari Holdings's Book Value per Share
For the Biotechnology subindustry, Dominari Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dominari Holdings's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dominari Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Dominari Holdings's PB Ratio falls into.
Dominari Holdings Book Value per Share Calculation
Dominari Holdings's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Dominari Holdings (NAS:DOMH) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Dominari Holdings Book Value per Share Related Terms
Thank you for viewing the detailed overview of Dominari Holdings's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Dominari Holdings (Dominari Holdings) Business Description
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is engaged in developing a therapeutic drug pipeline through partnerships with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore, and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company is also developing an antiviral platform, in which the compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DOMH has been successfully added to your 